Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)

The National Cancer Institute (NCI) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers for the years 2024, 2025, and 2026. This grant, which requires a P50 research center grant application, aims to fund top-notch, investigator-led translational research that can lead to advancements in the prevention, early screening, diagnosis, and treatment of specific organ-based cancers or closely related groups of cancers.

This could include cancers originating from the same organ system, such as gastrointestinal or head and neck cancers, among others. The focus of the research could also extend to groups of cancers sharing a common biological mechanism that promotes cancer development and progression in different organ systems. For instance, a SPORE-supported project might focus on cancers caused by the same infectious agent or those triggered and maintained by dysregulation of a common signaling pathway. The grant also accommodates projects focusing on overarching themes like pediatric cancers or cancer health disparities.

All research supported through this program should be translational, meaning that it applies scientific research to enhance human health and well-being. The methodological approaches may involve cellular, molecular, structural, biochemical, and/or genetic experimental methods, all anchored in human biology. Crucially, all projects funded under this program should work towards reaching a specific goal with human application within the lifespan of the grant.